

November 28, 2005

Jayne Peterson Advisors and Consultants Staff (HFD-21) Center for Drug Evaluation and Research Food and Drug Administration 5630 Fishers Lane Rockville, Maryland 20857

Via e-mail to petersonj@cder.fda.gov

CHPA's Nomination for Industry Liaison Representative to the Re:

Nonprescription Drugs Advisory Committee

Dear Ms. Peterson:

With this letter, the Consumer Healthcare Products Association (CHPA) expresses its great interest in the selection of the industry representative to serve on the Nonprescription Drugs Advisory Committee (NDAC), as requested in the Federal Register notice of November 15, 2005. CHPA has polled its members and identified George S. Goldstein, M.D., as the consensus candidate to be the industry representative on NDAC.

CHPA, founded in 1881, is the national trade organization representing manufacturers and distributors of nonprescription medicines and dietary supplements. By sales, CHPA members account for over 90 percent of the over-the-counter (OTC) drugs marketed in the United States. Throughout the years, the association has had an active interest in all aspects of OTC regulation, including Rx-to-OTC switch decisions as well as issues under the OTC review.

Given the association's strong presence in matters affecting nonprescription drugs, it is important for CHPA to participate in the selection process for the industry representative to NDAC. The majority of OTC drug issues will affect more CHPA members as an organization than any other industry trade group. We have consulted with other interested industry organizations about our nomination of Dr. Goldstein and will, as we have in the past, work to reach consensus with other industry organizations who notify FDA of their interest in participating in the selection process for the representative to NDAC.

900 19th Street, NW Washington, DC 20006 Tel: 202-429-9260 Fax: 202-223-6835

www.chpa-info.org

Jayne Peterson November 28, 2005 Page 2 of 2

As is evident from the attached resume, Dr. Goldstein has an impressive medical career history, including 14 years in private practice as a pediatrician and 15 years at Sterling Drug Inc. Among his many responsibilities at Sterling Drug was serving as Chief Medical Officer to the OTC drug division, Glenbrook Laboratories, as well as to the prescription drug division, Winthrop Laboratories. Dr. Goldstein has served as Chairman of the American Academy of Pediatrics' Section on Clinical Pharmacology and Therapeutics and as a member of the US Pharmacopeia Pediatric Advisory Committee.

Please call me at 202-429-3533 if you need additional information about Dr. Goldstein.

We look forward to your response.

doine C. Jotman

Sincerely,

Lorna C. Totman, Ph.D. Acting Vice President

Regulatory and Scientific Affairs

Attachment: Resume for George S. Goldstein, M.D., F.A.A.P.

cc:

Scott Gottlieb, M.D. Steven K. Galson, M.D., M.P.H. Deborah J. Henderson George S. Goldstein, M.D., F.A.A.P.